A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer
Interventions: DRUG: HLX11|DRUG: EU-Perjeta®
Sponsor: Shanghai Henlius Biotech